Avacta Reports Positive Phase 1a/1b Data for Faridoxorubicin in Salivary Gland Cancer

Avacta Group reported updated Phase 1a/1b trial data for faridoxorubicin (AVA6000), showing median progression-free survival of 11.4 months in a defined subset of patients with salivary gland cancer, compared with historical benchmarks of 6 to 6.7 months. The company also reported clinically meaningful tumor shrinkage in most patients in the subset. Avacta said the results support the potential of its pre|CISION platform to target drug payloads to tumors while limiting systemic toxicity.